Hello, everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap:
On Wednesday, ICER released its Draft Evidence Report assessing the comparative clinical effectiveness and value of icosapent ethyl (Vascepa®, Amarin Pharma) and rivaroxaban (Xarelto®, Janssen Pharmaceuticals), additive cardiovascular disease (CVD) therapies. The draft report will be open to public comment through August 20th.
EXCELSIOR ACTION POINT: : We had previously included Vascepa on our Drug Watch List owing to conflicting interpretations of limited data surrounding its cost- effectiveness. Effective with last week’s ICER release, we have removed Vascepa from the Drug Watch List, expecting ICER’s Final Report surrounding its cost-effectiveness to be favorable.
If you would like to discuss these ICER activities, or any other aspects of your Pharmacy Benefit Plan, simply reach out to your Excelsior Solutions account team and we will be happy to quickly set up a call.
Until next time!
Bob Kordella, RPh, MBA